Retatrutide trial shows 24% weight loss – is this the future?

Posted by greg208 in Research & News - 1 points, 0 comments.

org/peptides/retatrutide). The study had 120 participants with an average BMI of 34, and after 48 weeks the mean weight loss was 24 % – that's huge compared to the 12–15 % we see with GLP‑1 drugs alone. The triple agonist hits GIP, GLP‑1 and glucagon receptors, so the authors say the glucagon part ramps up energy expenditure and clears liver fat.

For me, that sounds exactly like the kind of metabolic boost that could help the post‑firefighting weight gain I struggled with after retirement. I’m not going to claim it’s a cure, but the data are compelling enough that I’m curious if anyone who’s tried a single‑receptor analogue (like liragrece or tirzepatide) has seen a difference in appetite or energy that could point to a real advantage from the triple action. Has anyone monitored heart rate or GI side‑effects with Retatrutide that could influence its tolerance in older adults?

Community discussion - research and educational context only. Not medical advice.